DaVita price target raised to $218 from $194 at Barclays
Barclays raised the firm's price target on DaVita to $218 from $194 and keeps an Equal Weight rating on the shares. The firm adjusted targets among its U.S. healthcare facilities and managed care coverage ahead of Q2 earnings from the group.